Copyright
©The Author(s) 2020.
World J Gastroenterol. Jun 28, 2020; 26(24): 3495-3516
Published online Jun 28, 2020. doi: 10.3748/wjg.v26.i24.3495
Published online Jun 28, 2020. doi: 10.3748/wjg.v26.i24.3495
Table 1 Over-the-scope clip types available for endoscope diameter and applicator clip depth2
OTSC cap options | ||||
Mini (10) | 11 | 12 | 14 | |
Scope outer diameter compatibility | 8.5-9.8 mm | 8.5-11 mm | 10.5-12 mm | 11.5-14 mm |
Diagnostic gastroscopes | Diagnostic gastroscopes | 1T/2T gastroscopes, peds colonoscopes | Adult colonoscopes | |
Maximum outer diameter of cap | 14.65 mm | 16.5 mm | 17.5 mm | 21 mm |
Thread length | 165 cm | 165 cm | 165 cm or 220 cm | 220 cm |
Depth of applicator cap | ||||
3 mm | a, t | a, t | a, t | a, t |
6 mm | N/A | a, t | a, t, gc1 | a, t |
Table 2 Summary of included studies (overall clinical success rate, per-indication clinical success rate, and overall over-the-scope clip-related adverse event rate)
Ref. | Year | Type of study | Country | Patients (n) | Overall clinical success rate (%) | Follow-up (wk) | Adverse events,n (%) | ||||||
Indications | Total | ||||||||||||
Fistula | Bleeding | Perforation | Leak | ER | Stent fixation | ||||||||
Seebach et al[15] | 2010 | Case series Retrospective | Switzerland | 7 | - | - | 57.1 | - | - | - | 57.1 | 10-42 | NR |
Kirschniak et al[2] | 2007 | Retrospective | Germany | 11 | - | 100 | 100 | - | 100 | - | 100 | 1-5 | 0.0 |
Mudumubi et al[16] | 2014 | Retrospective | International1 | 12 | - | - | - | - | - | 83.3 | 83.3 | 3-40 | 0.0 |
Sandmann et al[17] | 2011 | Case series Retrospective | Germany | 11 | 100 | - | 100 | 66 | 100 | - | 90.9 | 12.7 | NR |
Albert et al[18] | 2011 | Retrospective | Germany | 19 | - | 57.1 | - | 66.7 | - | - | 63.2 | 1-68 | 0.0 |
Repici et al[19] | 2009 | Case series Retrospective | Italy | 9 | - | 100 | - | - | 100 | - | 100 | 4-12 | 0.0 |
Donatelli et al[20] | 2016 | Retrospective | International2 | 45 | 36.7 | - | 100 | - | - | - | 57.8 | 36-100 | 0.0 |
Maekawa et al[21] | 2015 | Prospective | Japan | 12 | - | - | - | - | 91.7 | - | 91.7 | NR | 0.0 |
Gautier et al[22] | 2015 | Retrospective Multi-center | France | 17 | 11.8 | - | - | - | - | - | 11.8 | 12 | NR |
Nishiyama et al[23] | 2013 | Retrospective | Japan | 23 | 75 | 77.8 | 75 | - | 100 | - | 82.6 | 2-8 | 0.0 |
Voermans et al[24] | 2012 | Prospective Multi-center | Netherlands | 36 | - | - | 88.9 | - | - | - | 88.9 | 1-26 | 0.0 |
Lee et al[26] | 2017 | Prospective Multi-center | Korea | 19 | 25 | - | 100 | 83.3 | 100 | - | 73.7 | 72 | 0.0 |
Angsuwatcharakon et al[27] | 2016 | Retrospective | Thailand | 6 | - | - | 83.3 | - | - | - | 83.3 | NR | NR |
Arezzo et al[28] | 2012 | Case series Prospective | Italy | 14 | - | - | - | 85.7 | - | - | 85.7 | 16 | 0.0 |
Schlag et al[29] | 2013 | Prospective | Germany | 6 | - | - | 100 | - | - | - | 100 | 4-12 | 0.0 |
Disibeyaz et al[30] | 2012 | Case series Retrospective | Turkey | 9 | 33.3 | - | 100 | 60 | - | - | 55.6 | NR | 0.0 |
Gubler et al[31] | 2012 | Case series Prospective | Switzerland | 14 | - | - | 85.7 | - | - | - | 85.7 | 4-48 | NR |
Singhal et al[32] | 2014 | Case Series Prospective | United States | 10 | 90 | - | - | - | - | - | 90 | 7 | 0.0 |
Mennigen et al[33] | 2013 | Case series Retrospective | Germany | 14 | 71.4 | - | 100 | 83.3 | - | - | 78.6 | 1-68 | 0.0 |
Faehndrich et al[34] | 2015 | Retrospective | Germany | 17 | - | - | - | - | 94.1 | - | 94.1 | NR | 0.0 |
Schmidt et al[4] | 2015 | Prospective Multi-center RCT | International3 | 24 | - | - | - | - | 75 | - | 75 | 4 | 2 (8.3) |
Guo et al[35] | 2015 | Retrospective | China | 23 | - | - | - | - | 100 | - | 100 | 4-24 | 2 (8.7) |
Correia et al[36] | 2014 | Case series Prospective | Portugal | 6 | 80 | - | 100 | - | - | - | 83.3 | NR | 0.0 |
Goenka et al[37] | 2017 | Prospective | India | 12 | 66 | 100 | 100 | - | - | - | 91.7 | 4-8 | 0.0 |
Surace et al[38] | 2011 | Prospective | Italy | 19 | 73.7 | - | - | - | - | - | 73.7 | 32 | 1 (5.3) |
Kochhar et al[39] | 2017 | Case series Prospective | United States | 12 | - | - | - | 66.7 | - | - | 66.7 | 60 | 1 (8.3) |
Manta et al[40] | 2017 | Prospective | Italy | 76 | - | - | - | 80.3 | - | - | 80.3 | NR | 0.0 |
Parodi et al[41] | 2010 | Prospective | Italy | 10 | 80 | - | 100 | 50 | - | - | 80.0 | NR | 0.0 |
Manta et al[42] | 2011 | Case series Retrospective | Italy | 12 | 87.5 | - | - | 75 | - | - | 83.3 | 4 | 0.0 |
Honegger et al[43] | 2017 | Retrospective Cohort | Switzerland | 203 | 29.8 | 77.4 | 86.1 | 33.3 | - | 66.7 | 63.1 | 4 | 6 (3.0) |
Manno et al[44] | 2015 | Retrospective | International4 | 40 | - | 100 | - | - | - | - | 100 | 4 | 0.0 |
Richter-Schrag et al[45] | 2016 | Retrospective | Germany | 100 | - | 78 | - | - | - | - | 78 | NR | NR |
Aepli et al[46] | 2016 | Retrospective | Switzerland | 24 | - | - | - | - | 87.5 | - | 87.5 | NR | 4 (16.7) |
Law et al[48] | 2015 | Retrospective Multi-center | United States | 47 | 53.2 | - | - | - | - | - | 53.2 | 26 | 0.0 |
Farnik et al[3] | 2015 | Retrospective Multi-center | International5 | 34 | - | - | 100 | 56.3 | - | - | 70.5 | 39 | 0.0 |
Jacobsen et al[49] | 2012 | Retrospective | United States | 10 | 0 | - | 100 | 80 | - | - | 70.0 | 12 | 0.0 |
Haito-Chavez et al[50] | 2014 | Retrospective Multi-center | International6 | 161 | 42.9 | - | 90 | 73.3 | - | - | 60.2 | 18 – 30 | 0.0 |
Winder et al[51] | 2016 | Retrospective | United States | 28 | 77.2 | - | - | 100 | - | - | 82.1 | 19 | 0.0 |
Sulz et al[52] | 2014 | Case series Prospective | Switzerland | 19 | 54.5 | 100 | - | 66.7 | - | 100 | 63.1 | NR | 0.0 |
Magdeburg et al[53] | 2015 | Prospective | Germany | 43 | - | - | 97.8 | - | - | - | 97.8 | NR | 3 (7.0) |
Wedi et al[54] | 2016 | Retrospective | France | 84 | 100 | 89.3 | 57.1 | - | 100 | - | 89.3 | NR | 2 (2.4) |
Keren et al[55] | 2014 | Case series Prospective | Israel | 26 | - | - | - | 80.8 | - | - | 80.8 | NR | 0.0 |
Raithel et al[14] | 2017 | Retrospective Multi-center | Germany | 34 | - | - | 74.1 | 85.7 | - | - | 76.5 | NR | 3 (8.8) |
Kobara et al[56] | 2017 | Retrospective Multi-center | Japan | 58 | 83.3 | 83.3 | - | 85.7 | - | - | 84.5 | 4+ | 1 (1.8) |
Hagel et al[57] | 2012 | Case series Prospective | Germany | 17 | - | - | 64.7 | - | - | - | 64.7 | 4 | NR |
Nasa et al[58] | 2016 | Case series Retrospective | India | 7 | 80 | 100 | 100 | - | - | - | 85.7 | 45 | NR |
Skinner et al[6] | 2014 | Retrospective | United States | 12 | - | 83.3 | - | - | - | - | 83.3 | 10 – 30 | 0.0 |
Al-Bawardy et al[59] | 2017 | Retrospective | United States | 7 | - | - | - | - | 100 | - | 100 | 1 – 86 | 0.0 |
Sarker et al[60] | 2014 | Retrospective | United States | 8 | - | - | - | - | 100 | - | 100 | 4 – 52 | 0.0 |
Mangiavillano et al[61] | 2016 | Retrospective | Italy | 20 | - | - | 90 | - | - | - | 90 | 12 | NR |
Aiolfi et al[62] | 2014 | Retrospective | Italy | 7 | - | - | - | 85.7 | - | - | 85.7 | NR | NR |
Manta et al[5] | 2013 | Case series Multi-center | Italy | 30 | - | 90 | - | - | - | - | 90 | 1 – 4 | 0.0 |
Mangiafico et al[63] | 2017 | Case series Prospective | International7 | 7 | 100 | - | - | - | - | - | 100 | 2 – 8 | 0.0 |
Niland et al[64] | 2017 | Retrospective | United States | 14 | 21.4 | - | - | - | - | - | 21.4 | 26 | 0.0 |
Schmdtt et al[4] | 2018 | Prospective RCT | International8 | 33 | - | 84.8 | - | - | - | - | 84.8 | 4 | 0.0 |
Heinrich et al[65] | 2017 | Case series Retrospective | Switzerland | 5 | 100 | - | - | - | - | - | 100 | 46 – 269 | 0.0 |
Prosst et al[66] | 2015 | Prospective | Germany | 20 | 90 | - | - | - | - | - | 90 | 24 | 0.0 |
Mizrahi et al[67] | 2016 | Prospective | United States | 51 | 35.3 | 75 | 75 | 50 | - | 50 | 49.0 | 48 | NR |
Kirschniak et al[68] | 2011 | Retrospective | Germany | 46 | 37.5 | 93 | 100 | - | - | - | 84.8 | 1 – 2 | 0.0 |
Mennigen et al[69] | 2015 | Retrospective | Germany | 10 | 70 | - | - | - | - | - | 70 | 22 – 75 | 0.0 |
Wedi et al[70] | 2016 | Retrospective Case series | International9 | 6 | - | 100 | - | - | - | - | 100 | NR | NR |
Baron et al[71] | 2012 | Retrospective Multi-center | United States | 43 | 67.9 | 100 | 80 | 33.3 | - | - | 72.1 | 4 – 11 | 2 (4.7) |
Lamberts et al[72] | 2017 | Retrospective | Germany | 75 | - | 65.3 | - | - | - | - | 65.3 | NR | NR |
Soetikno et al[73] | 2016 | Case series Retrospective | International10 | 5 | - | 100 | - | - | - | - | 100 | 60 | 0.0 |
Wedi et al[74] | 2017 | Retrospective | International11 | 100 | - | 86 | - | - | - | - | 73 | NR | NR |
Chan et al[75] | 2014 | Case series Prospective | China | 9 | - | 77.8 | - | - | - | - | 77.8 | 8 | NR |
Keen et al[76] | 2019 | Prospective | United Kingdom | 59 | - | 93.2 | - | - | - | - | 93.2 | 4 | NR |
Horenkamp-Sonntag et al[77] | 2019 | Retrospective | Germany | 92 | - | 82.4 | 87.9 | - | - | - | 92.4 | 14 | NR |
Manta et al[78] | 2019 | Retrospective Multi-center | Italy | 286 | - | 94.4 | - | - | - | - | 94.4 | 4 | NR |
Mercky et al[79] | 2015 | Retrospective | France | 30 | 73.3 | - | - | - | - | - | 73.3 | 42 | 3 (10) |
Monkemuller et al[80] | 2014 | Case series Retrospective | Germany | 16 | 50 | 100 | - | 0 | 100 | 100 | 75 | 44 | 0.0 |
Bonino et al[81] | 2014 | Case series Prospective | Italy | 26 | 90 | - | 68.8 | - | - | - | 76.9 | NR | 0.0 |
Christophorou et al[82] | 2015 | Retrospective Multi-center | France | 14 | 78.5 | - | - | - | - | - | 78.5 | NR | NR |
Lunse et al[83] | 2019 | Retrospective | Germany | 9 | 66.7 | - | - | - | - | - | 66.7 | 8 | 0.0 |
Mosquera-Klinger et al[84] | 2019 | Retrospective Case series | Columbia | 14 | 70 | 100 | 100 | - | - | 100 | 78.6 | 20 | 0.0 |
Brander et al[25] | 2017 | Retrospective | United States | 67 | - | 70.1 | - | - | - | - | 70.1 | 4 | NR |
Meier et al[47] | 2017 | Retrospective | Germany | 10 | - | - | - | - | 100 | - | 100 | 12 | 0.0 |
Tashima et al[85] | 2017 | Prospective | Japan | 50 | - | - | - | - | 94 | - | 94 | 2 | 4 (8) |
Khater et al[86] | 2017 | Retrospective | France | 11 | - | - | 81.2 | - | - | - | 81.2 | NR | 1 (9) |
Asokkumar et al[87] | 2018 | Retrospective | International12 | 19 | - | 100 | - | - | - | - | 100 | NR | 0.0 |
Morrell et al[88] | 2019 | Retrospective | United States | 117 | 50.8 | - | - | 75 | - | - | 61.2 | 22 | 0.0 |
Kappelle et al[89] | 2018 | Prospective | Netherlands | 13 | - | - | - | - | 84.6 | - | 84.6 | 24 | 5 (38.4) |
Wei et al[90] | 2019 | Retrospective | China | 26 | - | - | 100 | - | - | - | 100 | 4 | 0.0 |
Golder et al[91] | 2019 | Retrospective | Germany | 100 | - | 75 | - | - | - | - | 75 | NR | 0.0 |
Wedi et al[92] | 2018 | Retrospective Multi-center | Germany | 118 | - | 92.4 | - | - | - | - | 92.4 | 4 | NR |
Total | 3025 | 55.8% | 86.0% | 85.3% | 72.6% | 92.8% | 80.0% | 78.4% | - | 2.1% | |||
347/622 | 1120/1303 | 399/468 | 284/391 | 205/221 | 16/20 | 2371/3025 | - | 40/194213 |
Table 3 Over-the-scope clip-related adverse events, per-indication
Table 4 Per-indication clinical success rate, technical success rate, and post-over-the-scope clip surgery rates
Clinical success rate (%), (n/N) | Technical success rate (%), (n/N) | Post-over the scope clip surgical rate (%), (n/N) | |
Fistula | 55.8 (347/622) | 92.8 (577/622) | 7.6 (47/622) |
Bleeding | 86.0 (1120/1303) | 96.8 (1261/1303) | 1.6 (21/1303) |
Perforation | 85.3 (399/468) | 95.5 (447/468) | 9.4 (44/468) |
Leak | 72.6 (284/391) | 86.7 (339/391) | 7.4 (29/391) |
ER | 92.8 (205/221) | 95.9 (212/221) | 0.9 (2/221) |
Stent fixation | 80.0 (16/20) | 100 (20/20) | 0.0 (0/20) |
Overall | 78.4 (2371/3025) | 94.4 (2856/3025) | 4.7 (143/3025) |
Table 5 Summary of prospective studies (overall clinical success rate, per-indication clinical success rate and adverse event rate)
Ref. | Year | Type of study | Country | Patients (n) | Overall clinical success rate (%) | Follow-up (wk) | Adverse events, n (%) | ||||||
Indications | Total | ||||||||||||
Fistula | Bleeding | Perforation | Leak | ER3 | Stent fixation | ||||||||
Maekawa et al[21] | 2015 | Prospective | Japan | 12 | - | - | - | - | 11/12 | - | 11/12 | NR | 0.0 |
Voermans et al[24] | 2012 | Prospective Multi-center | Netherlands | 36 | - | - | 32/36 | - | - | - | 32/26 | 1-26 | 0.0 |
Lee et al[26] | 2017 | Prospective Multi-center | Korea | 19 | 1/4 | - | 1/1 | 10/12 | 1/2 | - | 13/19 | 72 | 0.0 |
Arezzo et al[28] | 2012 | Case series Prospective | Italy | 14 | - | - | - | 12/14 | - | - | 12/14 | 16 | 0.0 |
Schlag et al[29] | 2013 | Prospective | Germany | 6 | - | - | 6/6 | - | - | - | 6/6 | 4-12 | 0.0 |
Gubler et al [31] | 2012 | Case series Prospective | Switzerland | 14 | - | - | 12/14 | - | - | - | 12/14 | 4-48 | NR |
Singhal et al[32] | 2014 | Case series Prospective | United States | 10 | 9/10 | - | - | - | - | - | 9/10 | 7 | 0.0 |
Schmidt et al[4] | 2015 | Prospective Multi-center RCT | International1 | 24 | - | - | - | - | 18/24 | - | 18/24 | 4 | 2 (8.3) |
Correia et al[36] | 2014 | Case series Prospective | Portugal | 6 | 4/5 | - | 1/1 | - | - | - | 5/6 | NR | 0.0 |
Goenka et al[37] | 2017 | Prospective | India | 12 | 2/3 | 6/6 | 3/3 | - | - | - | 11/12 | 4-8 | 0.0 |
Surace et al[38] | 2011 | Prospective | Italy | 19 | 14/19 | - | - | - | - | - | 14/19 | 32 | 1 (5.3) |
Kochhar et al[39] | 2017 | Case series Prospective | United States | 12 | - | - | - | 8/12 | - | - | 8/12 | 60 | 1 (8.3) |
Manta et al[40] | 2017 | Prospective | Italy | 76 | - | - | - | 61/76 | - | - | 61/76 | NR | 0.0 |
Parodi et al[41] | 2010 | Prospective | Italy | 10 | 4/5 | - | 3/3 | 1/2 | - | - | 8/10 | NR | 0.0 |
Sulz et al[52] | 2014 | Case series Prospective | Switzerland | 19 | 6/11 | 1/1 | - | 4/6 | - | 1/1 | 12/19 | NR | 0.0 |
Magdeburg et al[53] | 2015 | Prospective | Germany | 43 | - | - | 42/43 | - | - | - | 42/43 | NR | 3 (7.0) |
Keren et al[55] | 2014 | Case series Prospective | Israel | 26 | - | - | - | 21/26 | - | - | 21/26 | NR | 0.0 |
Hagel et al[57] | 2012 | Case series Prospective | Germany | 17 | - | - | 11/17 | - | - | - | 11/17 | 4 | NR |
Mangiafico et al[63] | 2017 | Case series Prospective | International2 | 7 | 7/7 | - | - | - | - | - | 7/7 | 2-8 | 0.0 |
Schmdtt et al[4] | 2018 | Prospective RCT | International3 | 33 | - | 28/33 | - | - | - | - | 28/33 | 4 | 0.0 |
Prosst et al[66] | 2015 | Prospective | Germany | 20 | 18/20 | - | - | - | - | - | 18/20 | 24 | 0.0 |
Mizrahi et al[67] | 2016 | Prospective | United States | 51 | 6/17 | 3/4 | 3/4 | 12/24 | - | 1/2 | 25/51 | 48 | NR |
Chan et al [75] | 2014 | Case series Prospective | China | 9 | - | 7/9 | - | - | - | - | 7/9 | 8 | NR |
Keen et al[76] | 2019 | Prospective | United Kingdom | 59 | - | 55/59 | - | - | - | - | 55/59 | 4 | NR |
Tashima et al[85] | 2017 | Prospective | Japan | 50 | - | - | - | - | 47/50 | - | 47/50 | 2 | 4 (8) |
Kappelle et al[89] | 2018 | Prospective | Netherlands | 13 | - | - | - | - | 11/13 | - | 11/13 | 24 | 5 (38.4) |
Total | 617 | 70.3% | 89.3% | 89.1% | 75.0% | 87.1% | 66.7% | 81.7% | - | 3.4% | |||
71/101 | 100/112 | 114/128 | 129/172 | 88/101 | 2/3 | 504/617 | - | 16/4674 |
- Citation: Bartell N, Bittner K, Kaul V, Kothari TH, Kothari S. Clinical efficacy of the over-the-scope clip device: A systematic review. World J Gastroenterol 2020; 26(24): 3495-3516
- URL: https://www.wjgnet.com/1007-9327/full/v26/i24/3495.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i24.3495